METHOD FOR INCLUDING BIOLOGICALLY ACTIVE COMPONENTS IN ERYTHROCYTES BY METHOD OF FLOW HYPOOSMOTIC DIALYSIS Russian patent published in 2023 - IPC A61K31/6615 A61K35/18 A61K38/50 C12M1/33 

FIELD: pharmaceutical industry.

SUBSTANCE: method for incorporating a biologically active component into erythrocytes by the method of flow hypoosmotic dialysis comprises the following steps: adding a biologically active component to a suspension of concentrated erythrocytes washed from whole blood or to a previously obtained erythromass; lysis of erythrocytes in the presence of at least one biologically active component using hypoosmotic flow dialysis; incubating a suspension of erythrocytes lysed in the presence of a biologically active component with a hyperosmotic solution to form sealed carrier erythrocytes containing at least one biologically active component; washing sealed erythrocyte carriers containing at least one biologically active component; concentrating, using a dialyzer, sealed carrier erythrocytes containing at least one biologically active component; washing out the sealed carrier erythrocytes remaining there from the dialyzer and adding them to previously obtained sealed carrier erythrocytes containing at least one biologically active component; while the stage of erythrocyte lysis in the presence of a biologically active component is carried out while maintaining a constant transmembrane pressure in the dialyzer of 160-180 mm Hg and pressure at the inlet to the internal circuit of the dialyzer not exceeding atmospheric by more than 120 mm Hg, and maintaining the temperature from +2°C to +10°C; washing of erythrocytes is carried out at room temperature; the concentration of erythrocytes is carried out while maintaining a constant transmembrane pressure in the dialyzer of 90-120 mm Hg taking into account the measured pressure indicators in the external and internal circuits of the dialyzer and maintaining the temperature from +2°C to +10°C; the stage of sealing lysed in the presence of a biologically active component or components of erythrocytes is carried out at a temperature of +25°C to +40°C; moreover, the stage of concentration of erythrocytes washed from whole blood and the stage of concentration of sealed erythrocyte carriers containing at least one biologically active component are carried out until the haematocrit value of the erythrocyte suspension is 75–80%.

EFFECT: above method allows for high efficiency and reproducible degree of incorporation of various biologically active components into erythrocytes, reducing the loss of intracellular content.

16 cl, 7 dwg, 2 tbl, 2 ex